Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novartis Group's Sandoz has launched US-based pharmaceutical firm Apricus Biosciences' Vitaros, a new topical on-demand treatment for erectile dysfunction (ED), in Sweden.
Subscribe to our email newsletter
In December 2013, Apricus expanded its exclusive license agreement with Hexal, an affiliate within Sandoz, for the commercialization of Vitaros in Austria, Belgium, Denmark, Finland, Iceland, Luxemburg, the Netherlands, Norway, Sweden and Switzerland (the Expanded Territory) in addition to Germany.
Apricus chief executive officer Richard Pascoe said the company is happy to announce the launch of Vitaros in Sweden, the first of the eleven territories to be commercialized by Sandoz, and considered an important and robust market for their European sales force.
"We continue to look forward to additional launches by our commercial partners expected throughout 2014," Pascoe said.
As part of the deal, Apricus is eligible to secure about $63m from Sandoz in upfront, regulatory, launch and sales milestone payments for Vitaros in Germany and the Expanded Territory, which includes up to $4.5m in new upfront and launch milestone compensation for the Expanded Territory.
Currently, Apricus is manufacturing multiple product batches through its contract manufacturer in Canada to support launches in Europe.